Sciencast Management’s NovoCure NVCR Stock Holding History

Sciencast Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$278K	Buy	4,149 +1,003	+32%	+$75.6K	0.06%	326
2022 Q1	$263K	Sell	3,146 -7,548	-71%	-$556K	0.06%	333
2021 Q4	$802K	Buy	10,694 +8,293	+345%	+$832K	0.14%	204
2021 Q3	$265K	Buy	+2,401	New	+$363K	0.08%	301
2021 Q2	–	Sell	-8,575	Closed	-$1.14M	–	628
2021 Q1	$1.14M	Buy	+8,575	New	+$1.36M	0.23%	134
2020 Q4	–	Sell	-4,650	Closed	-$622K	–	578
2020 Q3	$622K	Sell	4,650 -5,450	-54%	-$436K	0.24%	137
2020 Q2	$582K	Buy	+10,100	New	+$664K	0.15%	235
2020 Q1	–	Sell	-7,517	Closed	-$596K	–	494
2019 Q4	$596K	Buy	+7,517	New	+$607K	0.16%	210

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sciencast Management's NVCR Position: Q2 2022 in Review

Sciencast Management increased its NovoCure (NVCR) stake by 32% in Q2 2022, buying an estimated $75.6K and bringing the position to 4,149 shares worth $278K. The position accounts for 0.06% of the portfolio, ranked #326.

Sciencast Management first reported a position in NVCR in Q4 2019 and has held it in 8 quarters since. The position peaked at $1.14M in Q1 2021. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Sciencast Management held 4,149 shares of NovoCure worth $278K as of Q2 2022.
Sciencast Management bought 1,003 NovoCure shares in Q2 2022, an estimated $75.6K.
NovoCure made up 0.06% of Sciencast Management's portfolio in Q2 2022, its #326 holding.
Sciencast Management first reported a position in NovoCure in Q4 2019 and has held it in 8 quarters since.
Sciencast Management's NovoCure position peaked at $1.14M in Q1 2021.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Sciencast Management's 13F filing for Q2 2022, filed 3 Aug 2022.